thymoma type B3

Summary

thymoma type B3 (MONDO:0006458) is a disease and 3 clinical trials. Top therapeutic interventions include regorafenib. A subtype of thymoma type B — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	thymoma type B3
Mondo ID	MONDO:0006458
EFO	EFO:1000583
DOID	DOID:7926
NCIT	C7997
UMLS	C0279705
MedGen	124648
GARD	0024417
Is cancer (heuristic)	no

Also known as: atypical thymoma · epithelial malignant thymoma · epithelial thymoma · malignant thymoma type B3 · squamoid thymoma · thymoma type B3 · well differentiated thymic carcinoma · well-differentiated thymic carcinoma

Disease family

This is a subtype of thymoma type B. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › thymoma type B › thymoma type B3

Related subtypes (2): cortical thymoma, thymoma type B1

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03134118	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
NCT02307500	PHASE2	COMPLETED	Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
NCT04710628	PHASE2	COMPLETED	Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
REGORAFENIB	4	1